StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
598
This month
2
This week
2
This year
171
Today
1
Yesterday
1
Publishing Date
2023 - 10 - 31
3
2023 - 10 - 17
3
2023 - 09 - 26
3
2023 - 09 - 22
4
2023 - 06 - 08
3
2023 - 05 - 30
3
2023 - 05 - 01
3
2023 - 04 - 05
3
2023 - 02 - 02
3
2023 - 01 - 27
3
2022 - 08 - 10
3
2022 - 06 - 06
3
2022 - 06 - 03
3
2022 - 06 - 02
3
2022 - 04 - 12
4
2022 - 04 - 05
3
2022 - 02 - 25
3
2021 - 11 - 12
3
2021 - 11 - 03
3
2021 - 10 - 01
3
2021 - 09 - 17
3
2021 - 09 - 16
3
2021 - 09 - 08
3
2021 - 08 - 19
3
2021 - 07 - 30
3
2021 - 07 - 09
3
2021 - 06 - 25
3
2021 - 06 - 17
3
2021 - 06 - 11
2
2021 - 06 - 10
5
2021 - 06 - 09
2
2021 - 06 - 04
3
2021 - 06 - 02
2
2021 - 05 - 25
2
2021 - 05 - 24
3
2021 - 05 - 21
2
2021 - 05 - 20
5
2021 - 05 - 19
3
2021 - 05 - 18
4
2021 - 05 - 13
2
2021 - 05 - 12
3
2021 - 05 - 05
2
2021 - 04 - 29
3
2021 - 04 - 28
4
2021 - 04 - 23
5
2021 - 04 - 22
2
2021 - 04 - 16
4
2021 - 04 - 14
3
2021 - 04 - 13
3
2021 - 04 - 12
2
2021 - 04 - 07
3
2021 - 03 - 25
2
2021 - 03 - 19
3
2021 - 03 - 11
2
2021 - 03 - 04
2
2021 - 01 - 20
2
2021 - 01 - 11
2
2021 - 01 - 04
2
2020 - 12 - 11
3
2020 - 12 - 08
2
Sector
Commercial services
1
Communications
3
Consumer non-durables
1
Distribution services
1
Electronic technology
2
Energy minerals
3
Finance
10
Finance and insurance
1
Health services
5
Health technology
598
Information
2
Manufacturing
49
N/a
19
Process industries
10
Producer manufacturing
2
Professional, scientific, and technical services
3
Retail trade
4
Technology services
5
Tags
Agreement
7
Alliances
20
Antibody
13
Application
20
Approval
47
Biotech-bay
13
Cancer
102
Car-t
8
Cell
16
Cell carcinoma
11
Chmp
16
Clinical-trials-phase-ii
15
Clinical-trials-phase-iii
18
Collaboration
31
Conference
17
Disease
20
Drug
61
Earnings
21
Europe
16
Events
22
Expected
8
Fda
17
Financial
16
Financial results
17
Food
23
Genetown
8
Global
59
Growing
13
Growth
32
Immunotherapy
16
Int230
9
Iot
11
License
12
Lung
13
Market
106
Meeting
8
N/a
294
Nivolumab
58
Opdivo
31
People
13
Pharm-country
57
Pharmaceutical
11
Pharmaceuticals
8
Phase 1
10
Phase 2
15
Phase 3
12
Positive
26
Product-news
14
Psoriasis
8
Renal
11
Report
60
Research
73
Results
58
Solid tumors
10
T-cell
8
Therapeutics
40
Therapy
60
Treatment
82
Trial
45
Update
8
Entities
3m company
874
Abb ltd
1306
Abbott laboratories
1556
Abbvie inc.
918
Accenture plc
542
Alphabet inc.
1117
Amgen inc.
698
Apple inc.
1098
Arcelormittal
504
Arrival
3820
Astrazeneca plc
589
Athena consumer acquisition corp.
523
Becton, dickinson and company
724
Bnp paribas
1635
Boston scientific corporation
526
Bristol-myers squibb company
598
Broadcom inc.
523
Cisco systems, inc.
815
Danaher corporation
727
Dell technologies inc.
521
Dow inc.
522
Eli lilly and company
1555
Ericsson
1467
Extreme networks, inc.
581
First bank
558
Ford motor company
569
Gartner, inc.
531
General electric company
852
Glaxosmithkline plc
830
Honeywell international inc.
1621
Hubspot, inc.
1306
Intel corporation
882
International business machines corporation
606
Johnson & johnson
4001
Kering
1009
Koninklijke philips n.v.
887
Lithium corp
876
Live nation entertainment, inc.
718
Lockheed martin corporation
521
Medtronic plc
1198
Microsoft corporation
1128
Morgan stanley
3657
Nokia corp
887
Nokia corporation
825
Northrop grumman corporation
533
Novartis ag
1114
Novo nordisk a/s
568
Oracle corporation
1083
Orange
6135
Panasonic corp
592
Pfizer, inc.
645
Sanofi
4014
Sap se
1379
Snowflake inc.
709
Teva pharmaceutical industries ltd
567
Thermo fisher scientific inc
1435
Total se
1583
Verizon communications inc.
1065
Vision sensing acquisition corp.
504
X financial
569
Symbols
ABBV
74
ABT
24
ADCT
13
ADXS
8
ADXSD
7
AGIO
12
ALB
8
ALNY
10
ALPMF
6
ALPMY
6
ALXN
16
AMGN
73
AVEO
19
AYLA
12
AZN
53
AZNCF
45
BCRX
13
BGNE
11
BHC
9
BIIB
9
BLUE
8
BMY
598
BOLT
7
BPMC
19
CLVS
20
EPZM
18
EXEL
29
GILD
40
GLAXF
43
GSK
60
ILMN
10
INCY
23
INTS
12
JNJ
79
KPTI
19
LLY
95
MDT
6
MRTX
8
MYL
12
NEOS
13
NKTR
7
NVS
88
NVSEF
67
OMER
13
OTIC
13
PFE
60
REGN
29
REPL
6
RIGL
11
SNY
106
SNYNF
57
TAK
39
TEVA
8
TEVJF
28
TPTX
7
TSVT
8
VSTM
11
VTRS
14
XERS
10
YMAB
18
Exchanges
Amex
2
Lse
22
Nasdaq
356
Nyse
598
Tsx
4
Crawled Date
2023 - 09 - 26
3
2023 - 09 - 22
4
2023 - 09 - 18
3
2023 - 06 - 08
3
2023 - 06 - 01
3
2023 - 05 - 30
3
2023 - 05 - 01
3
2023 - 04 - 05
3
2023 - 02 - 02
3
2023 - 01 - 27
3
2022 - 08 - 10
3
2022 - 06 - 06
3
2022 - 06 - 03
3
2022 - 06 - 02
3
2022 - 04 - 12
4
2022 - 04 - 05
3
2022 - 02 - 25
3
2021 - 11 - 12
3
2021 - 11 - 03
3
2021 - 10 - 01
3
2021 - 09 - 17
3
2021 - 09 - 16
3
2021 - 09 - 08
3
2021 - 08 - 19
3
2021 - 07 - 30
3
2021 - 07 - 27
3
2021 - 07 - 09
3
2021 - 06 - 25
3
2021 - 06 - 11
2
2021 - 06 - 10
5
2021 - 06 - 09
2
2021 - 06 - 04
3
2021 - 06 - 02
2
2021 - 05 - 25
4
2021 - 05 - 21
2
2021 - 05 - 20
5
2021 - 05 - 19
3
2021 - 05 - 18
4
2021 - 05 - 13
2
2021 - 05 - 12
3
2021 - 05 - 05
2
2021 - 04 - 29
3
2021 - 04 - 28
4
2021 - 04 - 23
5
2021 - 04 - 22
2
2021 - 04 - 16
4
2021 - 04 - 15
2
2021 - 04 - 14
2
2021 - 04 - 13
4
2021 - 04 - 07
3
2021 - 03 - 29
2
2021 - 03 - 25
2
2021 - 03 - 19
3
2021 - 03 - 11
2
2021 - 03 - 04
2
2021 - 01 - 20
2
2021 - 01 - 11
2
2021 - 01 - 04
2
2020 - 12 - 11
3
2020 - 12 - 08
2
Crawled Time
00:00
16
00:01
1
01:00
8
02:00
6
03:00
2
04:00
2
04:20
2
05:00
1
06:00
3
07:00
4
08:00
5
08:20
1
09:00
4
10:00
8
10:41
1
10:43
1
10:51
2
10:57
1
11:00
22
11:36
1
12:00
101
12:01
1
12:02
1
12:04
1
12:15
15
12:20
17
12:24
1
12:30
9
12:34
1
13:00
64
13:07
1
13:13
1
13:15
4
13:17
1
13:20
10
13:27
1
13:30
3
13:50
1
14:00
34
14:03
1
14:15
1
14:20
7
14:30
5
14:58
1
15:00
27
15:01
1
15:15
2
15:20
4
16:00
29
16:20
3
17:00
23
18:00
19
18:04
2
18:26
2
18:31
2
19:00
15
20:00
20
21:00
25
22:00
19
23:00
13
Source
feed.businesswire.com
2
mindmed.co
1
savarapharma.com
1
www.biospace.com
303
www.fda.gov
46
www.globenewswire.com
44
www.prnewswire.com
201
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Bristol-myers squibb company
save search
Bristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab)
Published:
2023-12-07
(Crawled : 18:00)
- biospace.com/
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
0.76%
|
O:
1.04%
H:
1.39%
C:
-0.28%
opdivo
trial
plus
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Opdivo (nivolumab)
Published:
2023-12-05
(Crawled : 16:00)
- biospace.com/
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
Email alert
Add to watchlist
drug
opdivo
review
food
application
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
Published:
2023-11-28
(Crawled : 20:00)
- biospace.com/
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
2.33%
|
O:
0.06%
H:
0.55%
C:
-0.27%
RNA
|
$8.04
1.39%
1.37%
850K
|
Health Technology
|
30.68%
|
O:
25.32%
H:
3.63%
C:
-8.29%
expansion
collaboration
technology
cardiovascular
platform
Locally Advanced Pancreatic Cancer Market Report 2023-2028: Recent Advancements in Immunotherapy Inject New Hope into LAPC Market
Published:
2023-11-21
(Crawled : 23:00)
- prnewswire.com
AZNCF
|
$125.75
8.15%
2.6K
|
Health Technology
|
-0.59%
|
O:
0.36%
H:
0.0%
C:
-0.05%
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
3.47%
|
O:
0.56%
H:
1.53%
C:
1.37%
AZN
|
$63.5
-0.14%
-0.14%
6.2M
|
Health Technology
|
-1.2%
|
O:
-0.89%
H:
0.33%
C:
-0.16%
report
hope
cancer
pancreatic
immunotherapy
market
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Published:
2023-11-20
(Crawled : 13:00)
- biospace.com/
TSVT
|
$2.65
12.77%
11.32%
2.1M
|
|
22.69%
|
O:
-12.96%
H:
1.06%
C:
-7.45%
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-1.99%
|
O:
-4.69%
H:
2.85%
C:
0.25%
fda
review
update
therapy
FDA Roundup: November 17, 2023
Published:
2023-11-17
(Crawled : 22:00)
- prnewswire.com
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
Email alert
Add to watchlist
fda
HIV Drugs Market to Reach $51.1 Billion, Globally, by 2032 at 4.5% CAGR: Allied Market Research
Published:
2023-11-17
(Crawled : 16:00)
- prnewswire.com
JNJ
|
News
|
$155.4
-0.78%
-0.02%
6.4M
|
Health Technology
|
3.94%
|
O:
0.78%
H:
0.0%
C:
0.0%
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-1.34%
|
O:
0.67%
H:
0.0%
C:
0.0%
ABBV
|
News
|
$147.97
1.09%
0.05%
7.2M
|
Health Technology
|
7.01%
|
O:
0.01%
H:
0.0%
C:
0.0%
GILD
|
$78.03
-1.68%
-1.7%
8.2M
|
Health Technology
|
4.01%
|
O:
-0.13%
H:
0.0%
C:
0.0%
reach
research
hiv
market
Oncology Drugs Market worth $520 billion by 2033 - Exclusive Report by We Market Research
Published:
2023-11-10
(Crawled : 15:00)
- prnewswire.com
PFE
A
|
$28.63
-0.56%
0.0%
35M
|
Health Technology
|
-8.38%
|
O:
-4.83%
H:
0.0%
C:
0.0%
JNJ
|
News
|
$155.4
-0.78%
-0.02%
6.4M
|
Health Technology
|
3.58%
|
O:
-1.24%
H:
0.0%
C:
0.0%
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-4.4%
|
O:
-3.68%
H:
0.0%
C:
0.0%
ABBV
|
News
|
$147.97
1.09%
0.05%
7.2M
|
Health Technology
|
7.19%
|
O:
0.44%
H:
0.0%
C:
0.0%
AZN
|
$63.5
-0.14%
-0.14%
6.2M
|
Health Technology
|
-2.54%
|
O:
-2.88%
H:
0.0%
C:
0.0%
report
research
market
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Published:
2023-11-10
(Crawled : 12:30)
- prnewswire.com
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-4.4%
|
O:
-3.68%
H:
0.0%
C:
0.0%
MRTX
|
$56.64
-0.02%
-0.02%
2.3M
|
Health Technology
|
0.82%
|
O:
-0.11%
H:
0.0%
C:
0.0%
krasg12
lung
chmp
positive
cancer
cell
treatment
therapeutics
Tempus Announces Research Collaboration with Bristol Myers Squibb to Apply Multimodal AI Approaches
Published:
2023-11-08
(Crawled : 20:00)
- biospace.com/
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-5.09%
|
O:
-0.62%
H:
0.11%
C:
-0.19%
research
collaboration
HARMONY BIOSCIENCES APPOINTS PETER ANASTASIOU TO ITS BOARD OF DIRECTORS
Published:
2023-11-08
(Crawled : 13:00)
- prnewswire.com
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-5.09%
|
O:
-0.62%
H:
0.11%
C:
-0.19%
STIM
|
$1.8
-4.76%
-5.0%
55K
|
Health Technology
|
31.39%
|
O:
5.11%
H:
0.0%
C:
0.0%
HRMY
|
News
|
$31.07
-3.09%
-3.19%
780K
|
Health Technology
|
23.98%
|
O:
-2.78%
H:
0.59%
C:
-1.72%
Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Published:
2023-11-06
(Crawled : 15:00)
- biospace.com/
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-2.62%
|
O:
3.16%
H:
0.77%
C:
-0.66%
MRTX
|
$56.64
-0.02%
-0.02%
2.3M
|
Health Technology
|
1.78%
|
O:
0.75%
H:
0.59%
C:
0.27%
therapeutics
financial
results
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
Published:
2023-11-06
(Crawled : 13:00)
- globenewswire.com
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-2.62%
|
O:
3.16%
H:
0.77%
C:
-0.66%
al102
drug
tumors
pharmaceuticals
designation
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
Published:
2023-11-02
(Crawled : 12:00)
- globenewswire.com
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-3.11%
|
O:
-1.84%
H:
1.08%
C:
0.61%
MRTX
|
$56.64
-0.02%
-0.02%
2.3M
|
Health Technology
|
1.59%
|
O:
0.2%
H:
0.43%
C:
-0.38%
KURA
|
$11.27
1.81%
1.77%
800K
|
Health Technology
|
34.52%
|
O:
-4.76%
H:
6.0%
C:
5.25%
ko-2806
collaboration
therapeutics
agreement
Bristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
Published:
2023-10-31
(Crawled : 00:00)
- biospace.com/
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-3.0%
|
O:
-0.65%
H:
0.0%
C:
0.0%
AMGEN REPORTS THIRD QUARTER FINANCIAL RESULTS
Published:
2023-10-31
(Crawled : 11:00)
- prnewswire.com
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-3.0%
|
O:
-0.65%
H:
0.0%
C:
0.0%
XNCR
|
$20.2
4.88%
4.65%
500K
|
Health Technology
|
16.96%
|
O:
-0.46%
H:
0.0%
C:
0.0%
SNY
|
News
|
$46.06
0.17%
0.17%
1.9M
|
Health Technology
|
2.97%
|
O:
2.61%
H:
0.0%
C:
0.0%
REGN
|
News
|
$849.57
1.65%
1.63%
560K
|
Health Technology
|
8.96%
|
O:
-0.51%
H:
0.0%
C:
0.0%
BGNE
J
|
$182.01
-1.16%
-1.18%
180K
|
Health Technology
|
-3.16%
|
O:
1.38%
H:
0.0%
C:
0.0%
AMGN
S
|
$271.33
0.74%
0.73%
2M
|
Health Technology
|
2.32%
|
O:
-3.22%
H:
0.0%
C:
0.0%
financial
results
Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
Published:
2023-10-31
(Crawled : 06:00)
- biospace.com/
MS
|
News
0 d
|
$80.35
1.18%
-0.03%
5.3M
|
Finance
|
14.59%
|
O:
0.83%
H:
0.0%
C:
0.0%
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-3.0%
|
O:
-0.65%
H:
0.0%
C:
0.0%
MRTX
|
$56.64
-0.02%
-0.02%
2.3M
|
Health Technology
|
2.27%
|
O:
0.46%
H:
0.0%
C:
0.0%
Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
Published:
2023-10-30
(Crawled : 13:00)
- biospace.com/
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-1.69%
|
O:
1.35%
H:
0.0%
C:
0.0%
KPTI
|
$0.8353
-1.83%
-1.87%
750K
|
Health Technology
|
1.72%
|
O:
2.92%
H:
6.08%
C:
-3.35%
collaboration
trial
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
Published:
2023-10-26
(Crawled : 13:00)
- biospace.com/
XYF
|
News
0 d
|
$3.76
1.62%
2.39%
18K
|
Finance
|
3.77%
|
O:
2.29%
H:
4.87%
C:
4.87%
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-11.39%
|
O:
-4.68%
H:
2.46%
C:
-1.83%
MRTX
|
$56.64
-0.02%
-0.02%
2.3M
|
Health Technology
|
2.68%
|
O:
0.16%
H:
0.47%
C:
0.2%
financial
results
Global HIV Diagnostics Market Predicted to Reach $1.5 Billion by 2030, with a CAGR of 5.5%
Published:
2023-10-25
(Crawled : 18:00)
- prnewswire.com
BMY
|
News
P
|
$50.16
0.56%
0.0%
14M
|
Health Technology
|
-10.76%
|
O:
-0.34%
H:
1.34%
C:
1.05%
GILD
|
$78.03
-1.68%
-1.7%
8.2M
|
Health Technology
|
-0.13%
|
O:
-0.31%
H:
0.89%
C:
0.62%
reach
global
hiv
diagnostics
market
← Previous
1
2
3
4
5
6
7
8
9
…
29
30
Next →
Gainers vs Losers
69%
31%
Top 10 Gainers
SLDB
|
News
M
|
$5.89
72.22%
41.94%
12M
|
Health Technology
SVFD
|
News
|
$3.09
43.72%
30.42%
64M
|
FTEL
|
$2.04
43.66%
30.39%
110K
|
HPCO
4
|
$0.4824
41.92%
29.54%
28M
|
ALGS
|
News
|
$0.6475
-5.06%
26.67%
2.1M
|
Health Technology
GTHX
|
$3.16
30.58%
23.42%
10M
|
Health Technology
KEQU
|
$22.5
27.62%
21.64%
24K
|
Producer Manufacturing
GSIT
|
$3.09
27.16%
21.36%
2.2M
|
Electronic Technology
SSKN
P
|
$0.628
25.6%
20.38%
210K
|
Health Technology
GLUE
|
$3.66
22.82%
18.58%
510K
|
Professional, Scientific, and T...
Your saved searches
Save your searches and get alerts when important news are released.